Abdala (vaccine)

Abdala is a COVID-19 vaccine developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba. It is a protein subunit vaccine, which uses a harmless piece of the virus to trigger an immune response in the body.

Development and Testing[edit | edit source]

The development of Abdala began in 2020, in response to the global COVID-19 pandemic. The vaccine was named after a poem by the Cuban national hero, José Martí. The vaccine underwent three phases of clinical trials, with the results indicating a high level of efficacy against the virus.

Efficacy[edit | edit source]

According to the data released by the Cuban health authorities, Abdala has an efficacy rate of 92.28% after three doses. This makes it one of the most effective vaccines in the world, comparable to the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine.

Administration[edit | edit source]

Abdala is administered in three doses, with a two-week interval between each dose. The vaccine is injected into the muscle of the upper arm, similar to other COVID-19 vaccines.

Side Effects[edit | edit source]

Common side effects of the Abdala vaccine include pain at the injection site, fatigue, headache, muscle pain, and fever. These side effects are usually mild and go away on their own within a few days.

Global Use and Distribution[edit | edit source]

As of August 2021, Abdala has been authorized for use in several countries, including Cuba, Venezuela, and Nicaragua. The Cuban government has also expressed its intention to offer the vaccine to tourists visiting the country.

See Also[edit | edit source]

Abdala (vaccine) Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.